Tumors can and do disappear, both with medical treatment and, in rare cases, entirely on their own. Malignant tumors of nearly every tissue type have been documented shrinking or vanishing without therapy, a phenomenon called spontaneous regression. Meanwhile, modern cancer treatments including surgery, chemotherapy, radiation, immunotherapy, and targeted drugs routinely eliminate tumors in millions of patients each year. But the full picture is more complicated than a simple yes or no, because the biology of tumor disappearance, the risk of recurrence, and the meaning of “gone” all depend on the type of growth, the body’s immune response, and how closely you look at what gets left behind.
Spontaneous Regression Is Real but Extremely Rare
Doctors and researchers have known for over a century that some cancers vanish without treatment. Spontaneous regression has been recorded in tumors of almost every histological type, though certain cancers regress far more often than others.1PubMed Central. Spontaneous regression of malignant tumors: Importance of the immune system and other factors (Review) Kidney cancer, melanoma, neuroblastoma, and some blood cancers show up disproportionately in the case-report literature. The overall rate is difficult to pin down because cases go unreported or unrecognized, but estimates typically place it somewhere around one in every 60,000 to 100,000 cancer diagnoses.
The key driver appears to be the immune system. When researchers look at what the regression cases have in common, immune activation keeps surfacing as the central theme. Some regressions follow acute infections, fevers, or other immune-stimulating events, which fits the idea that the body’s defenses occasionally mount an effective attack on a tumor they had previously been ignoring.2PubMed Central. Spontaneous regression of tumour and the role of microbial infection–possibilities for cancer treatment A striking recent example involved two patients with metastatic kidney cancer whose tumors regressed after they caught COVID-19. Both had predominantly lung and lymph-node involvement, and their tumors shrank measurably within three to four months of the infection.3PubMed Central. Spontaneous Regression of Metastatic Renal Cell Carcinoma after SARS-CoV-2 Infection: A Report of Two Cases
To be clear, spontaneous regression is defined as recovery from cancer in the absence of adequate disease-specific treatment. That means no chemotherapy, no radiation, no immunotherapy that would explain the result. It is not a treatment strategy anyone should count on. But its existence tells researchers something important about the immune system’s latent capacity to fight cancer, and that insight has directly influenced the development of immunotherapy drugs that try to recreate the effect deliberately.
Cancers That Regress More Often
Neuroblastoma, a cancer that primarily affects young children, is one of the best-studied examples of spontaneous regression in oncology. Some neuroblastomas, particularly those diagnosed in infants, shrink and disappear without any treatment at all. Researchers have identified several mechanisms that may explain this, including the loss of an enzyme that maintains chromosome stability (telomerase), epigenetic changes, immune responses, and the delayed activation of a built-in cell-death program that developing nerve cells normally undergo.4PubMed Central. Mechanisms of neuroblastoma regression In practical terms, this means some infant neuroblastomas behave less like aggressive cancer and more like a developmental detour that the body eventually corrects.
Renal cell carcinoma (kidney cancer) is another tumor where spontaneous regression pops up more than expected. The kidney cancer cases are particularly interesting because regression has sometimes been observed after the primary kidney tumor was surgically removed but before any other treatment was given. The removal of the primary tumor appears to sometimes “unmask” the immune system’s ability to attack remaining metastatic deposits. Melanoma, certain lymphomas, and a handful of other cancer types also appear on the short list of tumors that occasionally vanish on their own, and immune activation is the common thread tying most of these cases together.5Journal of Oncological Science. Spontaneous tumor regression
Benign Tumors and Precancerous Growths Can Shrink Too
The conversation around tumors disappearing usually focuses on cancer, but many benign (non-cancerous) growths also shrink or resolve, sometimes predictably. Uterine fibroids are a common example. These muscle-tissue tumors of the uterus are hormone-dependent, and they tend to shrink after menopause as estrogen levels drop. A ten-year follow-up study of nearly 100 women found that fibroids shrank fastest in the first two years after menopause, then continued to decrease more gradually over the following years.6PubMed Central. Postmenopausal Shrinkage of Uterine Myomas: A Retrospective Study of 97 Cases Monitored Annually for 10 Years Hormone-suppressing drugs can also force fibroids to shrink before menopause. In one study, treatment with a hormone-blocking agent produced roughly a 55% reduction in uterine volume over six months, with the biggest drop happening in just the first treatment cycle.7Fertility and Sterility. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot
Precancerous lesions sit in between benign growths and full cancers, and some of these also regress spontaneously. High-grade cervical dysplasia (the kind of cell changes that can eventually become cervical cancer) provides one of the clearest examples. Research has shown that certain women clear these lesions on their own, and the likelihood of clearance depends in part on the specific strain of HPV involved and on genetic factors related to how the immune system recognizes infected cells.8PubMed Central. Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotype This is one reason that guidelines for managing cervical abnormalities sometimes include a period of watchful waiting rather than immediate surgery.
How Standard Cancer Treatments Eliminate Tumors
For the vast majority of cancer patients, tumor disappearance happens because of treatment, not despite the lack of it. Surgery physically removes the growth. Chemotherapy and radiation damage or destroy cancer cells directly. But the story of how these treatments actually work has gotten more nuanced as researchers learn more about the immune system’s role.
Radiation therapy, for instance, does not just kill tumor cells through DNA damage. The debris left behind by dying cancer cells gets picked up by immune cells, which then process and present pieces of the dead tumor to the adaptive immune system. This can train the body to recognize and attack surviving cancer cells that the radiation missed, including cancer cells in completely different parts of the body.9PubMed Central. Dying cell clearance and its impact on the outcome of tumor radiotherapy This phenomenon, where radiation aimed at one tumor causes a distant tumor to shrink, is called the abscopal effect.10PubMed Central. A Review of the Abscopal Effect in the Era of Immunotherapy It was considered a medical curiosity for decades, but it has gained serious attention now that immunotherapy drugs can amplify it.
Targeted therapies work through a different logic. Some cancers are driven primarily by a single mutated gene or protein, and drugs that block that specific target can shut down the tumor’s growth and survival signals. The concept behind this approach is that even though cancer cells accumulate many genetic defects, the tumor sometimes depends on just one dominant driver. Block that driver, and the cancer collapses.11PubMed Central. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils Drugs like imatinib for certain leukemias and crizotinib for certain lung cancers exemplify this strategy. The tumors can shrink dramatically, sometimes within weeks.
Immunotherapy and Reawakening the Immune System
Immunotherapy represents something of a bridge between spontaneous regression and conventional treatment. Instead of attacking the tumor directly, checkpoint inhibitor drugs remove the brakes that cancers put on the immune system. Tumors often survive by displaying molecular signals that tell approaching immune cells to stand down. Checkpoint inhibitors block those signals, freeing the immune system to mount the kind of attack that spontaneous regression cases suggest was always possible in principle.12PubMed Central. The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances
Combining immunotherapy with radiation has been especially promising for triggering the abscopal effect. Preclinical research shows that successful abscopal responses are characterized by improved blood flow to the distant tumor, reduced oxygen starvation within it, and lower metabolic activity, all signs that the immune system has gained access and is actively working.13PubMed Central. Improved Tumor Blood Flow Enhances the Abscopal Effect: Preclinical Assessment in Mice Treated with Combined Radiation and PD-1 Blockade Therapy The abscopal effect still occurs inconsistently, however, and researchers are actively trying to figure out why it works in some patients and not others.
When a Growing Tumor Is Actually Responding
One of the more confusing aspects of immunotherapy is that tumors sometimes appear to grow before they shrink. On imaging scans, a tumor treated with checkpoint inhibitors can look larger in the weeks after treatment starts. If you did not know about this pattern, you might conclude the treatment had failed. In reality, the increase in apparent size can be caused by immune cells flooding into the tumor, which makes it swell temporarily. The tumor then shrinks as the immune response takes hold. This is called pseudoprogression.14PubMed Central. How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy
Pseudoprogression matters because mistaking it for true progression can lead doctors and patients to stop an immunotherapy drug that is actually working.15PubMed Central. Pseudoprogression and Immunotherapy Phenomena The frequency varies by cancer type, but it is not the majority pattern. Most tumors that grow on immunotherapy are genuinely progressing. The challenge is distinguishing the two, and oncologists use a combination of follow-up scans, symptom assessment, and newer imaging techniques to tell them apart. For patients, the practical takeaway is that a single scan showing growth shortly after starting immunotherapy does not necessarily mean the treatment has failed.
Why “Gone” Does Not Always Mean Gone for Good
Even when a tumor disappears completely on scans and in blood tests, microscopic cancer cells can persist. These dormant cells are among the most frustrating problems in oncology. They can lodge in bone marrow, the liver, the brain, or other organs and remain quiescent for years, sometimes decades, before reactivating and causing a recurrence.16PubMed Central. Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence Breast cancer is particularly notorious for late recurrences. Disseminated tumor cells that persist in bone marrow are independently associated with breast cancer recurrence and death, even many years after apparently successful initial treatment.17Nature Medicine. Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial
Research in animal models has shown that residual tumor cells surviving targeted therapy can enter a dormant state even when they have adequate blood supply and no immune system actively suppressing them. They simply stop dividing. But they retain the ability to wake up and start growing again after long periods of quiet.18PubMed Central. Cellular dormancy in minimal residual disease following targeted therapy This is why oncologists recommend years of follow-up after treatment, and why some patients take maintenance medications for five or ten years after their primary tumor is gone. The tumor may have disappeared, but the potential for its return has not necessarily vanished with it.
When a Biopsy Itself Triggers Regression
An odd corner of the spontaneous-regression literature involves tumors that shrink after a diagnostic biopsy. In a reported breast cancer case, the physical trauma of the biopsy needle appeared to trigger a local immune response strong enough to cause the tumor to regress temporarily.19PubMed Central. Transient Regression of Breast Carcinoma After Diagnostic Biopsy and Tumor Heterogeneity: A Case Report The hypothesis is that the tissue damage from the needle exposed tumor material to immune cells in a way that the intact tumor had been avoiding. This is conceptually similar to how radiation debris primes the immune system, as described earlier, but achieved accidentally through mechanical disruption.
These cases are rare and the regression is often temporary, so no one is proposing biopsies as cancer treatment. But they add to the broader picture that the immune system often has the latent capacity to attack a tumor if given the right trigger. The tumor’s ability to hide from immune surveillance is not always absolute, and small disruptions can sometimes break through that camouflage.
Tumors That Fight Back Against Treatment
Understanding tumor disappearance also means understanding the ways tumors resist disappearing. Cancers are not static targets. They evolve under the pressure of treatment, and some develop metabolic workarounds that let them survive drugs designed to starve them. Anti-angiogenic therapies, for example, work by cutting off a tumor’s blood supply. This produces measurable but often temporary shrinkage. In pancreatic neuroendocrine tumors studied in mouse models, cancer cells adapted by establishing a metabolic relay system: oxygen-starved cells in the tumor’s interior imported glucose and exported lactate, while better-oxygenated cells on the periphery consumed that lactate as fuel. This cooperation allowed the tumor to survive the blood-supply blockade.20Cell Press. Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy in Pancreatic Neuroendocrine Tumors The finding helps explain why certain anti-angiogenic drugs produce initial tumor shrinkage that does not last.
Glioblastoma, the most aggressive brain tumor, illustrates another kind of resistance. When blood vessels within the tumor become occluded and oxygen drops, the surviving cancer cells do not simply die. Instead, they migrate outward from the low-oxygen core, secreting signals that stimulate new blood vessel growth ahead of them. The result is a tumor that expands outward precisely because its center is dying.21Laboratory Investigation. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma This cycle of internal collapse fueling external expansion makes glioblastoma exceptionally difficult to eradicate.
Lessons from an Ancient Transmissible Cancer in Dogs
One of the more surprising windows into tumor regression comes from a cancer that has been around for thousands of years. Canine transmissible venereal tumor (CTVT) is a contagious cancer in dogs that spreads through direct physical contact. It is one of only three known clonally transmissible cancers in nature, along with devil facial tumor disease in Tasmanian devils and certain leukemias in clams. Among the three, CTVT is the only one that spontaneously regresses.22PubMed Central. Mechanistic Insights into Transmissible Cancers of Mammals
In most dogs, CTVT initially grows as a visible mass, then the immune system mounts an effective rejection response and the tumor disappears. Genome-wide analysis of this process has shown that regression involves activation of the host’s innate immune genes and a shift in tumor-cell gene expression toward a more differentiated, less cancerous state. Changes in DNA methylation patterns accompany this transition.23Cancer Cell. Systematic Analysis of Canine Transmissible Venereal Tumor Regression The fact that this cancer reliably regresses in most affected dogs, driven by the same innate immune mechanisms that researchers are trying to harness in human immunotherapy, makes it a uniquely valuable natural model. It demonstrates that tumor-cell differentiation and immune-mediated rejection can work together to eliminate an established cancer, a principle that underlies some of the most promising directions in human cancer treatment.24PubMed. Immunobiology of a spontaneously regressive tumor, the canine transmissible venereal sarcoma
Cellular Senescence as a Natural Brake
Not all tumor cells that stop growing are dormant in the traditional sense. Some enter a state called cellular senescence, where they permanently lose the ability to divide. Unlike dormant cells, which are merely quiet and can potentially restart, senescent cells do not respond to growth signals at all.25BMB Reports. Cellular senescence: a promising strategy for cancer therapy Senescence can be triggered by DNA damage, including damage caused by chemotherapy or radiation, and it serves as a built-in safety mechanism that prevents cells with dangerous mutations from continuing to multiply.
This is a double-edged phenomenon, however. While senescent cells stop dividing, they remain metabolically active and secrete a cocktail of inflammatory molecules. In some contexts, this secretion can promote inflammation that supports the growth of nearby non-senescent cancer cells. Research into drugs that selectively kill senescent cells, called senolytics, is exploring whether clearing these zombie-like cells after treatment could reduce the risk of recurrence and improve outcomes. The science is still early, but the concept reflects a growing appreciation that tumor elimination is not just about killing dividing cells; it is also about managing what the non-dividing remnants do to the surrounding tissue.